Caris Life Sciences Launches AI-Driven Profiling Tool for Tumors

The Genomic Profiling Similarity Score uses over 6,500 mathematical models in a machine learning algorithm to compare molecular characteristics of a patient's tumor against Caris' extensive database.

Caris Life Sciences

Irving-based molecular science startup Caris Life Sciences has launched its AI-driven MI GPS Score, the newest addition to its comprehensive genomic profiling offerings to help guide decision-making in tumor treatments.

The MI GPS (Genomic Profiling Similarity) Score is an AI-driven tumor type biology similarity score, which uses more than 6,500 mathematical models in a machine-learning algorithm to compare molecular characteristics of a patient’s tumor against Caris’ extensive database, according to a statement.

It is expected to provide new insights into the molecular subtype of cancer of unknown primary cases (CUP), atypical clinical presentation cases, and other difficult to treat cancer cases, according to Caris. CUP is a disease in which cancer cells are found in the body, but the place where the cancer started is unknown.

The Caris team of pathologists reviews the case with the additional information provided by the tumor type similarity score, which compares molecular characteristics of the patient’s tumor against the company’s database.


READ NEXT Irving-based Caris Life Sciences is Expanding its Footprint Here With a New Corporate Park


“Caris has the world’s largest and most comprehensive database of paired molecular information with clinical outcomes,” David Spetzler, Caris’ president and chief scientific officer, said in a statement. “We are actively employing advanced machine learning capabilities with this data set to identify unique molecular signatures that our industry-leading pathologists can use to better identify cancer subtypes and predict patient response to certain therapies.”

Spetzler noted that combining AI and human intelligence “provides the most comprehensive analysis available today to characterize a patient’s tumor.”

Caris noted that previous data shared at the 2019 American Society of Clinical Oncology Annual Meeting showed this score classified tumors from over 55,000 samples with more than 95 percent accuracy and generated an unequivocal result in most CUP cases when there was ambiguity about the tissue of origin.

Earlier this month, Caris also announced a partnership with Ambry Genetics, a leading clinical genetic testing company. 

Through the partnership, Caris plans to begin offering Ambry’s 67-gene CancerNext-Expanded panel, which when combined with Caris’ tumor tests is expected to form the most comprehensive, clinically relevant molecular and genetic offering on the market to guide the treatment and management of cancer.

In May, Caris Life Sciences acquired Pharmatech Inc. to redefine cancer treatment by pairing each patient with the right clinical trial, regardless of their location, in as little as 10 days.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.
View previous emails.

R E A D   N E X T

Comments are closed.